Hydrochlorothiazide
JFDA label: Uniretic Tablets
Mechanism of Action
Inhibitor of Solute carrier family 12 member 3 — Thiazide-sensitive sodium-chloride cotransporter inhibitor
| Target | Action | Gene / class |
|---|---|---|
| Solute carrier family 12 member 3 efficacy | INHIBITOR | SLC12A3 |
Indications
Approved
- Chronic kidney disease (CKD) and hypertension
- Coronary artery disease (CAD) and hypertension
- Diabetes and hypertension
- Edema
- Hypertension
Off-label
- Calcium nephrolithiasis
- Lithium-induced diabetes insipidus
Contraindications
Source: Lexicomp
- Additional contraindications (not in US labeling): Increasing azotemia and oliguria during treatment of severe progressive renal disease Absolute
- Hypersensitivity to hydrochlorothiazide, any component of the formulation, or sulfonamide-derived drugs Absolute
- anuria Note: Although some product labeling states this medication is contraindicated with other sulfonamide-containing drug classes, the scientific basis of this statement has been challenged. See “Warnings/Precautions” for more detail Absolute
- breast-feeding Documentation of allergenic cross-reactivity for thiazide-related diuretics is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty Absolute
Adverse Reactions
Cardiac disorders (3)
Not Known Hypotension · necrotizing angiitis · orthostatic hypotension
Nervous system disorders (5)
Not Known Dizziness · headache · paresthesia · restlessness · vertigo
Hepatobiliary disorders (1)
Not Known Jaundice
Renal and urinary disorders (4)
Not Known Impotence · Interstitial nephritis · renal failure · renal insufficiency
Blood and lymphatic system disorders (6)
Not Known Agranulocytosis · aplastic anemia · hemolytic anemia · leukopenia · purpura · thrombocytopenia
Immune system disorders (1)
Not Known Anaphylaxis
Metabolism and nutrition disorders (13)
Common Hyperglycaemia · Hyperlipidaemia · Hyperuricaemia · Hypokalaemia
Uncommon Hyponatraemia
Not Known Glycosuria · hypercalcemia · hyperglycemia · hyperuricemia · hypochloremic alkalosis · hypokalemia · hypomagnesemia · hyponatremia
Gastrointestinal disorders (9)
Not Known Abdominal cramps · anorexia · constipation · diarrhea · gastric irritation · nausea · pancreatitis · sialadenitis · vomiting
Skin and subcutaneous tissue disorders (9)
Uncommon Photosensitivity
Not Known Alopecia · erythema multiforme · exfoliative dermatitis · skin photosensitivity · skin rash · Stevens-Johnson syndrome · toxic epidermal necrolysis · urticaria
Musculoskeletal and connective tissue disorders (2)
Not Known Muscle spasm · weakness
Eye disorders (2)
Not Known Transient blurred vision · xanthopsia
General disorders and administration site conditions (1)
Not Known Fever
Respiratory, thoracic and mediastinal disorders (3)
Not Known pneumonitis · pulmonary edema · Respiratory distress
Dosing
Source: Lexicomp
Warnings & Precautions
Source: Lexicomp
Electrolyte disturbances
Hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia may occur. Development of electrolyte disturbances can be minimized when used in combination with other electrolyte sparing antihypertensives (eg, ACE inhibitors or angiotensin receptor blockers) (Sica 2011).
Gout
In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide. This risk may be increased with doses ≥25 mg (Gurwitz 1997).
Hypersensitivity reactions
Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.
Ocular effects
May cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation. Discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain; additional treatments may be needed if uncontrolled intraocular pressure persists. Risk factors may include a history of sulfonamide or penicillin allergy.
Photosensitivity
Photosensitization may occur.
Sulfonamide (“sulfa”) allergy
The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO2NH2). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes. Disease-related concerns:
Adrenal insufficiency
Avoid use of diuretics for treatment of elevated blood pressure in patients with primary adrenal insufficiency (Addison disease). Adjustment of glucocorticoid/mineralocorticoid therapy and/or use of other antihypertensive agents is preferred to treat hypertension (Bornstein 2016; Inder 2015).
Ascites due to cirrhosis
Use with extreme caution or avoid hydrochlorothiazide in the management of ascites due to cirrhosis; may lead to rapid development of hyponatremia when used in combination with spironolactone and furosemide (AASLD [Runyon 2012]).
Diabetes
Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.
Hepatic impairment
Use with caution in patients with severe hepatic dysfunction; in progressive or severe liver disease, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy/coma.
Hypercalcemia
Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.
Hypercholesterolemia
Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported.
Hypokalemia
Use with caution in patients with hypokalemia; correct before initiating therapy.
Parathyroid disease
Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use; should be discontinued prior to testing for parathyroid function.
Renal impairment
Cumulative effects may develop, including azotemia, in patients with impaired renal function. Avoid in severe renal disease (ineffective).
Systemic lupus erythematosus (SLE)
May cause SLE exacerbation or activation. Concurrent drug therapy issues:
Drug-drug interactions
Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Special populations:
Surgical patients
If given the morning of surgery, hydrochlorothiazide may render the patient volume depleted and blood pressure may be labile during general anesthesia. Dosage form specific issues:
Propylene glycol
Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.
Pregnancy & Lactation
Pregnancy
Adverse events have not been observed in animal reproduction studies. Hydrochlorothiazide crosses the placenta. Maternal use may cause may cause fetal or neonatal jaundice, thrombocytopenia, or other adverse events observed in adults. Use of thiazide diuretics to treat edema during normal pregnancies is not appropriate; use may be considered when edema is due to pathologic causes (as in the nonpregnant patient); monitor. Untreated chronic maternal hypertension is associated with adverse events in the fetus, infant, and mother (ACOG 2013). Women who required thiazide diuretics for the treatment of hypertension prior to pregnancy may continue their use (ACOG 2013).
Lactation
Hydrochlorothiazide is present in breast milk. The relative infant dose (RID) of hydrochlorothiazide is 0.6% to 1.2% when compared to an infant therapeutic dose of 1 to 2 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is The RID of hydrochlorothiazide was calculated using a mean milk concentration of 80 ng/mL from a single case report, providing an estimated daily infant dose via breast milk of 0.012 mg/kg/day. This milk concentration was obtained following matern
Monitoring
| Clinical pearl | Blood pressure, dizziness, lightheadedness; sodium, potassium, BUN, creatinine; skin to assess for photosensitivity, skin cancer |
|---|
Chemistry & Properties
| Formula | C7H8ClN3O4S2 |
|---|---|
| Molecular weight | 297.75 g/mol |
| IUPAC name | 6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide |
| CAS | 58-93-5 |
| PubChem CID | 3639 |
| InChIKey | JZUFKLXOESDKRF-UHFFFAOYSA-N |
| logP | -0.35 (XLogP -0.1) |
| Polar surface area | 118.36 Ų |
| H-bond acceptors / donors | 5 / 3 |
| Drug-likeness (QED) | 0.65 |
| Lipinski violations | 0 |
SMILES
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=OBiology & Pharmacokinetics
Pharmacokinetics predicted
| Bioavailability | 10.0% |
|---|---|
| Half-life | 0.853 h |
| Volume of distribution | 0.867 L/kg |
| Protein binding | 62.5% |
| BBB penetrant | No |
Receptor binding (top 1)
| Target | Action | Affinity |
|---|---|---|
| N-Acylphosphatidylethanolamine-phospholipase D (NAPEPLD) | Allosteric modulator | pKd 6.1 |
Transporters
ASBT (Inhibitor)BCRP (Inhibitor)BCRP (Inhibitor)BSEP (Inhibitor)BSEP (Inhibitor)MCT6 (Inhibitor)MRP1 (Inhibitor)MRP2 (Inhibitor)MRP3 (Inhibitor)MRP4 (Inhibitor)OAT1 (Inhibitor)OAT2 (Inhibitor)OAT3 (Inhibitor)OAT4 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)OATP1B3 (Inhibitor)OCT1 (Inhibitor)OCTN2 (Inhibitor)P-gp (Inhibitor)MDR1 (Substrate)OAT1 (Substrate)OAT2 (Substrate)OAT3 (Substrate)P-gp (Substrate)
Drug–drug interactions (100+, DDInter)
| Interacting drug | Severity | Management |
|---|---|---|
| Aminolevulinic acid | major | |
| Arsenic trioxide | major | |
| Cisapride | major | |
| Dolasetron | major | |
| Acarbose | moderate | |
| Acetohexamide | moderate | |
| Albiglutide | moderate | |
| Aldesleukin | moderate | |
| Alimemazine | moderate | |
| Alogliptin | moderate | |
| Amifostine | moderate | |
| Aminolevulinic acid (topical) | moderate | |
| Amphotericin B | moderate | |
| Amphotericin B (cholesteryl sulfate) | moderate | |
| Amphotericin B (lipid complex) | moderate | |
| Amphotericin B (liposomal) | moderate | |
| Beclomethasone dipropionate | moderate | |
| Betamethasone | moderate | |
| Bisacodyl | moderate | |
| Brimonidine (ophthalmic) | moderate | |
| Brimonidine (topical) | moderate | |
| Bupropion | moderate | |
| Calcifediol | moderate | |
| Calcipotriol (topical) | moderate | |
| Calcitriol | moderate | |
| Calcitriol (topical) | moderate | |
| Calcium Phosphate | moderate | |
| Calcium acetate | moderate | |
| Calcium carbonate | moderate | |
| Calcium chloride | moderate | |
| Calcium citrate | moderate | |
| Calcium glubionate anhydrous | moderate | |
| Calcium glucoheptonate | moderate | |
| Calcium gluconate | moderate | |
| Calcium lactate | moderate | |
| Canagliflozin | moderate | |
| Capecitabine | moderate | |
| Castor oil | moderate | |
| Celecoxib | moderate | |
| Chlorpropamide | moderate |
Showing 40 of 100+.
Registered Products (162)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| JOSWE HCT | Tablet 12.5 mg | 30 tab | joswe medical | 1.500 |
| Monozide | Tablet 12.5 mg | 30 tab pack varies | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 1.500 |
| Modrex 25 Tablets | Tablet 25 mg | 20 tab pack varies | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 1.740 |
| AMURETIC TAB. | Tablet 50 mg, 5 mg | 20 tab pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 1.800 |
| Uniretic Tablets | Tablet 50 mg, 5 mg | 20 tab pack varies | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 2.090 |
| JOSWE HCT | Tablet 25 mg | 30 tab | joswe medical | 2.460 |
| Co-Irda 150mg/12.5 mg | Tablet 150 mg, 12.5 mg | 28 tab | Ibn Rushd Drug Store | 2.620 |
| Monozide 25 tablet | Tablet 25 mg | 30 tab pack varies | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 2.650 |
| Co-Irda 300mg/12.5 mg | Tablet 300 mg, 12.5 mg | 28 tab | Ibn Rushd Drug Store | 3.110 |
| Co-Irda 300mg/25mg F.C.T | Tablet 300 mg, 25 mg | 28 tab | Ibn Rushd Drug Store | 3.110 |
| Cardiosafe Plus 5/12.5 tab | Tablet 12.5 mg, 5 mg | 30 tab | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 3.500 |
| Coronasart Plus | Tablet 16 mg, 12.5 mg | 30 tab | Nabulsi Drug Store | 3.630 |
| Promivol-Plus 5/6.25 F.C Tab | Film-Coated Tablet 6.25 mg, 5 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 3.900 |
| Promivol-plus 5mg/12.5mg | Tablet 12.5 mg, 5 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 3.900 |
| Coronasart Plus | Tablet 8 mg, 12.5 mg | 30 tab | Nabulsi Drug Store | 4.120 |
| Tenstar Plus 80/12.5 | Tablet 12.5 mg, 80 mg | 30 tab | JORDAN RIVER PHARMA.IND(JORIVER)/JORDAN | 4.130 |
| Arbaval Plus 160/12.5 mg FC Tablet | Film-Coated Tablet 12.5 mg, 160 mg | 28 tab | Ibn Rushd Drug Store | 4.310 |
| Arbaval Plus 160/25 mg FC Tablet | Film-Coated Tablet 25 mg, 160 mg | 28 tab | Ibn Rushd Drug Store | 4.310 |
| Procard Plus 150/12.5 | Tablet 150 mg, 12.5 mg | 30 tab | Al-Taqqadom Pharmaceutical Industries | 4.380 |
| Concor 5 Plus F.C Tab | Film-Coated Tablet 12.5 mg, 5 mg | 30 tab | Nabulsi Drug Store | 4.450 |
| Co-Tabuvan | Tablet 12.5 mg, 80 mg | 30 tab | Sukhtian Group | 4.670 |
| Irbegen Plus | Tablet 150 mg, 12.5 mg | 30 tab | Orient Montreal Drug Store | 4.720 |
| Irbegen Plus | Tablet 300 mg, 25 mg | 30 tab | Orient Montreal Drug Store | 4.720 |
| Irbegen Plus | Tablet 300 mg, 12.5 mg | 30 tab | Orient Montreal Drug Store | 4.720 |
| Valsartan Sandoz Plus 80mg/12.5mg | Tablet 12.5 mg, 80 mg | 28 tab | Nabulsi Drug Store | 4.900 |
| Blopress 8 Plus Tab | Tablet 12.5 mg, 8 mg | 28 tab | The Arab Pharmaceutical Manufacturing PSC/Salt | 5.020 |
| Co-Diotens 80/12.5 | Tablet 12.5 mg, 80 mg | 30 tab | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 5.070 |
| Lacine Plus Tab | Tablet 12.5 mg, 50 mg | 30 tab | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 5.180 |
| Lacine Plus Tab | Tablet 25 mg, 100 mg | 30 tab | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 5.360 |
| Lacine Plus Tab | Tablet 12.5 mg, 100 mg | 30 tab | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 5.360 |
| Gardia plus (8mg/12.5mg) Tab | Tablet 12.5 mg, 8 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 5.380 |
| Co-Tabuvan | Tablet 12.5 mg, 160 mg | 30 tab | Sukhtian Group | 5.390 |
| Co-Tabuvan 160/25 Tab | Tablet 25 mg, 160 mg | 30 tab | Sukhtian Group | 5.390 |
| Hyzaar 100mg/12.5mg | Tablet 12.5 mg, 100 mg | 28 tab | Adatco Drug Store | 5.560 |
| Procard Plus | Tablet 300 mg, 12.5 mg | 30 tab pack varies | Al-Taqqadom Pharmaceutical Industries | 5.630 |
| Valsartan Sandoz Plus160mg/12.5mg | Tablet 12.5 mg, 160 mg | 28 tab | Nabulsi Drug Store | 5.660 |
| Valsartan Sandoz Plus 160mg/25mg | Tablet 25 mg, 160 mg | 28 tab | Nabulsi Drug Store | 5.660 |
| Vivazac Plus 150/12.5 mg F.C Tab | Film-Coated Tablet 150 mg, 12.5 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 5.730 |
| Vivazac Plus 300/12.5 mg F.C Tab | Film-Coated Tablet 300 mg, 12.5 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 5.730 |
| Vivazac Plus 300/25 mg F.C Tab | Film-Coated Tablet 300 mg, 25 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 5.730 |
| Hyzaar 50mg/12.5mg | Tablet 12.5 mg, 50 mg | 30 tab | Adatco Drug Store | 5.750 |
| CAPOCARD PLUS TABS. | Tablet 50 mg, 25 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 5.760 |
| Zestoretic Tablet | Tablet (anhydrous) 20 mg, 12.5 mg | 28 tab | Shawi & Rushedat Drug Store | 5.790 |
| Co-Diotens 160/12.5 m | Tablet 12.5 mg, 160 mg | 30 tab | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 5.920 |
| Co-Diotens 160/25 | Tablet 25 mg, 160 mg | 30 tab | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 5.920 |
| Gizlan -Plus 150mg/12.5mg | Tablet 150 mg, 12.5 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 5.990 |
| Gizlan Plus | Tablet 300 mg, 12.5 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 5.990 |
| Gizlan-Plus | Tablet 300 mg, 25 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 5.990 |
| Nebilet Plus 5mg/12.5mg | Tablet 12.5 mg, 5 mg | 30 tab | ORIENT DRUG STORE CO | 5.990 |
| Nebilet Plus 5mg/25mg | Tablet 25 mg, 5 mg | 30 tab | ORIENT DRUG STORE CO | 5.990 |
| Cardiosafe Plus 10/25 tab | Tablet 25 mg, 10 mg | 30 tab | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 6.000 |
| Co-Diovan Tab | Tablet 12.5 mg, 80 mg | 28 tab | The Jordan Drugstore Co | 6.130 |
| Promivol-Plus 10/25 F.C Tab | Film-Coated Tablet 25 mg, 10 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 6.180 |
| Promivol-Plus 10/6.25 F.C Tab | Film-Coated Tablet 6.25 mg, 10 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 6.180 |
| Arbiten Plus 80/12.5 Tablet | Tablet 12.5 mg, 80 mg | 30 tab pack varies | JORDAN SWEDEN MEDICAL&STERILE.CO(JOSWE)/JORDAN | 6.240 |
| Co-Aprovel | Tablet 150 mg, 12.5 mg | 28 tab | Ulfa Pharma Co. | 6.240 |
| Co-Aprovel | Tablet 300 mg, 12.5 mg | 28 tab | Ulfa Pharma Co. | 6.240 |
| Co-Aprovel | Tablet 300 mg, 25 mg | 28 tab | Ulfa Pharma Co. | 6.240 |
| Co-Anginet | Tablet 12.5 mg, 80 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 6.330 |
| Diostar-Plus | Film-Coated Tablet 12.5 mg, 80 mg | 30 F.C Tab | Pharma International Company/ Jordan | 6.330 |
| Blopress 16 plus Tab | Tablet 12.5 mg, 16 mg | 28 tab | The Arab Pharmaceutical Manufacturing PSC/Salt | 6.460 |
| Vasorex Plus (5/25) mg Tab | Tablet 25 mg, 5 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 6.470 |
| Vasorex plus | Tablet 12.5 mg, 5 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 6.470 |
| Vilasar-Plus 80/12.5 mg F.C Tab | Film-Coated Tablet 12.5 mg, 80 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 6.480 |
| Oletran Plus | Tablet 12.5 mg, 20 mg | 30 tab | Pharma International Company/ Jordan | 6.810 |
| Mycardio HCTZ Tablet 80/12.5 | Tablet Hydrochlorothiazide 12.5 mg, Telmisartan 80 mg | 30 tab | Al-Motakadema Pharmaceutical LTD. | 6.850 |
| Gardia Plus (16/12.5mg)Tab | Tablet 12.5 mg, 16 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 6.920 |
| Jocanda Plus | Tablet 12.5 mg, 16 mg | 30 tab | JORDAN SWEDEN MEDICAL&STERILE.CO(JOSWE)/JORDAN | 6.920 |
| Triprel Plus | Tablet 25 mg, 5 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 6.940 |
| Tenstar Plus 160/12.5 | Tablet 12.5 mg, 160 mg | 30 tab | JORDAN RIVER PHARMA.IND(JORIVER)/JORDAN | 7.050 |
| Tenstar Plus 160/25 | Tablet 25 mg, 160 mg | 30 tab | JORDAN RIVER PHARMA.IND(JORIVER)/JORDAN | 7.050 |
| Arbaval Plus 320/25 mg FC Tablet | Film-Coated Tablet 25 mg, 320 mg | 28 tab | Ibn Rushd Drug Store | 7.070 |
| Co-Diovan Tab | Tablet 12.5 mg, 160 mg | 28 tab | The Jordan Drugstore Co | 7.080 |
| Co-Diovan Tab | Tablet 25 mg, 160 mg | 28 tab | The Jordan Drugstore Co | 7.080 |
| Atacand Plus | Tablet 12.5 mg, 16 mg | 28 tab | Shawi & Rushedat Drug Store | 7.180 |
| Arbiten Plus 160/12.5 Tablet | Tablet 12.5 mg, 160 mg | 30 tab pack varies | Jordan Sweden Medical & Sterilization Co. | 7.190 |
| Arbiten plus Tablet | Tablet 25 mg, 160 mg | 30 tab pack varies | Jordan Sweden Medical & Sterilization Co. | 7.190 |
| Co-Anginet | Tablet 25 mg, 160 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 7.190 |
| Co-Anginet | Tablet 12.5 mg, 160 mg | 30 tab pack varies | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 7.190 |
| Diostar-Plus | Tablet 25 mg, 160 mg | 30 tab | Pharma International Company/ Jordan | 7.550 |
| Diostar-Plus | Film-Coated Tablet 12.5 mg, 160 mg | 30 F.C Tab pack varies | Pharma International Company/ Jordan | 7.630 |
| Vilasar-Plus 160/12.5 mg F.C Tab | Film-Coated Tablet 12.5 mg, 160 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 7.700 |
| Vilasar-Plus 160/25mg F.C Tab | Film-Coated Tablet 25 mg, 160 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 7.700 |
| Mozart HCT | Tablet 20 mg, 25 mg | 30 tab | Dar Al Dawa Development and Investment | 7.860 |
| Mozart HCT | Tablet 20 mg, 12.5 mg | 30 tab | Dar Al Dawa Development and Investment | 7.860 |
| Vasorex Plus (10/12.5) mg Tab | Tablet 12.5 mg, 10 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 7.860 |
| Vasorex plus | Tablet 25 mg, 10 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 7.860 |
| Lotevan Plus Film Coated Tablets 5/160/12.5 | Film-Coated Tablet 12.5 mg, 160 mg, 5 mg | 30 tab | Sukhtian Group | 8.010 |
| Lotevan Plus Film Coated Tablets 5/160/25 | Film-Coated Tablet 25 mg, 160 mg, 5 mg | 30 tab | Sukhtian Group | 8.010 |
| Lotevan Plus Film Coated Tablets 10/160/12.5 | Film-Coated Tablet 12.5 mg, 160 mg, 10 mg | 30 tab | Sukhtian Group | 8.120 |
| Lotevan Plus Film Coated Tablets 10/160/25 | Film-Coated Tablet 25 mg mg, 160 mg, 10 mg | 30 tab | Sukhtian Group | 8.120 |
| Oletran Plus | Tablet 12.5 mg, 40 mg | 30 tab | Pharma International Company/ Jordan | 8.400 |
| Olmetec Plus 20/12.5 | Tablet 12.5 mg, 20 mg | 28 tab | Salam Drug Store | 8.460 |
| Olmetec Plus 20/25 | Tablet 25 mg, 20 mg | 28 tab | Salam Drug Store | 8.460 |
| Votum Plus 20/25 mg F.C Tab | Film-Coated Tablet 25 mg, 20 mg | 28 tab | ORIENT DRUG STORE CO | 8.670 |
| Votum Plus 20mg/12.5mg F.C Tab | Film-Coated Tablet 12.5 mg, 20 mg | 28 tab | ORIENT DRUG STORE CO | 8.670 |
| ValHart TRIO 5/160/12.5mg FC Tablets | Film-Coated Tablet 12.5 mg, 160.00 mg, 6.935 mg | 30 tab | Petra Pharmaceutical Industries | 8.690 |
| Olvans plus | Tablet 12.5 mg, 20.0 mg | 30 tab | SAVVY PHARMA/JORDAN | 8.760 |
| Olmetec Plus 40/12.5 | Tablet 12.5 mg, 40 mg | 28 tab | Salam Drug Store | 8.780 |
| Olmetec Plus 40/25 | Tablet 25 mg, 40 mg | 28 tab | Salam Drug Store | 8.780 |
| Senergy Plus (5/160/25) Mg F.C Tab | Film-Coated Tablet 25 mg, 160 mg, 5 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 8.780 |
| Senergy Plus(5/160/12.5) mg F.c Tab | Film-Coated Tablet 12.5 mg, 160 mg, 5 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 8.780 |
| Angiozide tablet | Tablet 12.5 mg, 20 mg | 20 tab | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 9.000 |
| Micardis Plus Tab | Tablet 12.5 mg, 80 mg | 28 tab | The Jordan Drugstore Co | 9.140 |
| ValHart TRIO 10/160/12.5mg FC Tablets | Film-Coated Tablet 12.5 mg, 160.00 mg, 13.87 mg | 30 tab | Petra Pharmaceutical Industries | 9.160 |
| Mozart HCT | Tablet 40 mg, 12.5 mg | 30 tab | Dar Al Dawa Development and Investment | 9.690 |
| Mozart HCT | Tablet 40 mg, 25 mg | 30 tab | Dar Al Dawa Development and Investment | 9.690 |
| Co-Diotens 320/12.5 | Tablet 12.5 mg, 320 mg | 30 tab | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 9.700 |
| Co-Diotens 320/25 | Tablet 25 mg, 320 mg | 30 tab | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 9.700 |
| Co-Tabuvan | Tablet 25 mg, 320 mg | 30 tab | Sukhtian Group | 10.040 |
| Co-Tabuvan | Tablet 12.5 mg, 320 mg | 30 tab | Sukhtian Group | 10.040 |
| Senergy Plus(10/160/12.5) mg F.C Tab | Film-Coated Tablet 12.5 mg, 160 mg, 10 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 10.250 |
| Senergy Plus(10/320/25) Mg F.C Tab | Film-Coated Tablet 25 mg, 320 mg, 10 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 10.250 |
| Senergy plus (10/160/25) mg F.C Tab | Film-Coated Tablet 25 mg, 160 mg, 10 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 10.250 |
| Angiosar Plus 160/10/12.5 f.c tab | Film-Coated Tablet 12.5 mg, 160 mg, 10 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 10.690 |
| Angiosar-Plus | Tablet 25 mg, 320 mg, 10 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 10.690 |
| Angiosar-Plus 160/5/12.5 F.C Tab | Film-Coated Tablet 12.5 mg, 160 mg, 5 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 10.690 |
| Angiosar-plus160/5/25 F.C tab | Film-Coated Tablet 25 mg, 160 mg, 5 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 10.690 |
| Vilasar-Plus 320/25 mg F.C Tab | Film-Coated Tablet 25 mg, 320 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 10.690 |
| Votum Plus 40/12.5 mg F.C Tab | Film-Coated Tablet 12.5 mg, 40 mg | 28 tab | ORIENT DRUG STORE CO | 10.700 |
| Votum Plus 40/25 mg F.C tab | Film-Coated Tablet 25 mg, 40 mg | 28 tab | ORIENT DRUG STORE CO | 10.700 |
| Olvans plus | Tablet 12.5 mg, 40.0 mg | 30 tab | SAVVY PHARMA/JORDAN | 10.800 |
| Olvans plus | Tablet 25.0 mg, 40.0 mg | 30 tab | SAVVY PHARMA/JORDAN | 10.800 |
| Combitran Plus | Tablet 12.5 mg, 10 mg, 40 mg | 30 tab | Pharma International Company/ Jordan | 10.940 |
| Combitran Plus | Tablet 12.5 mg, 5 mg, 40 mg | 30 tab | Pharma International Company/ Jordan | 10.940 |
| Newstar Plus | Tablet 25 mg, 10 mg, 160 mg | 28 tab | Pharma International Company | 11.030 |
| Newstar Plus | Tablet 12.5 mg, 10 mg, 160 mg | 28 tab | pharma international | 11.030 |
| Newstar Plus | Tablet 25 mg, 5 mg, 160 mg | 28 tab | pharma international | 11.030 |
| Newstar Plus | Tablet 12.5 mg, 5 mg, 160 mg | 28 tab | pharma international | 11.030 |
| Combizart HCT | Tablet 25 mg, 5 mg, 40 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 11.100 |
| Combizart HCT | Tablet 12.5 mg, 5 mg, 40 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 11.100 |
| Combizart HCT | Tablet 25 mg, 10 mg, 40 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 11.100 |
| Combizart HCT | Tablet 12.5 mg, 10 mg, 40 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 11.100 |
| Combizart HCT | Tablet 12.5 mg, 5 mg, 20 mg | 30 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 11.100 |
| Capozide Tablets | Tablet 50 mg, 25 mg | 28 tab | Suleiman Tannous & Sons Co. Ltd | 11.340 |
| Gardia Plus 32mg/25mg Tab | Tablet 25 mg, 32 mg | 30 tab | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 11.350 |
| Jocanda Plus | Tablet 25 mg, 32 mg | 30 tab | JORDAN SWEDEN MEDICAL&STERILE.CO(JOSWE)/JORDAN | 11.350 |
| Tenstar Plus | Tablet 25 mg, 320 mg | 30 tab | JORDAN RIVER PHARMA.IND(JORIVER)/JORDAN | 11.550 |
| Exforge HCT 5/160/12.5 | Tablet 12.5 mg, 160 mg, 5 mg | 28 tab | The Jordan Drugstore Co | 11.590 |
| Exforge HCT 5/160/25 | Tablet 25 mg, 160 mg, 5 mg | 28 tab | The Jordan Drugstore Co | 11.590 |
| Exforge HCT 10/160/12.5 | Tablet 12.5 mg, 160 mg, 10 mg | 28 tab | The Jordan Drugstore Co | 12.220 |
| Exforge HCT 10/160/25 | Tablet 25 mg, 160 mg, 10 mg | 28 tab | The Jordan Drugstore Co | 12.220 |
| Joswe Potenza Plus | Tablet 12.5 mg, 160 mg, 5 mg | 30 tab | Jordan Sweden Medical & Sterilization Co. | 12.810 |
| Lotevan Plus Film Coated Tablets 10/320/25 | Film-Coated Tablet 25 mg mg, 320 mg, 10 mg | 30 tab | Sukhtian Group | 13.320 |
| Vocado HCT 20/5/12.5 mg F.C Tab | Film-Coated Tablet 12.5 mg, 5 mg, 20 mg | 28 tab | ORIENT DRUG STORE CO | 13.650 |
| Vocado HCT 40/10/12.5 mg F.C tab | Film-Coated Tablet 12.5 mg, 10 mg, 40 mg | 28 tab | ORIENT DRUG STORE CO | 13.650 |
| Vocado HCT 40/10/25 mg F.C Tab | Film-Coated Tablet 25 mg, 10 mg, 40 mg | 28 tab | ORIENT DRUG STORE CO | 13.650 |
| Vocado HCT 40/5/12.5 mg F.C Tab | Film-Coated Tablet 12.5 mg, 5 mg, 40 mg | 28 tab | ORIENT DRUG STORE CO | 13.650 |
| Vocado HCT 40/5/25 mg F.C Tab | Film-Coated Tablet 25 mg, 5 mg, 40 mg | 28 tab | ORIENT DRUG STORE CO | 13.650 |
| Teveten Plus | Tablet 12.5 mg, 600 mg | 28 tab | Abu Sheikha Drug Store | 18.680 |
| Joswe Potenza Plus | Tablet 25 mg, 320 mg, 10 mg | 30 tab | Jordan Sweden Medical & Sterilization Co. | 19.050 |
| AMURETIC TAB. | Tablet 50 mg, 5 mg | 500 tab pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 36.900 |
| Monozide | Tablet 12.5 mg | 1005 tab pack varies | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 42.710 |
| Uniretic Tablets | Tablet 50 mg, 5 mg | 1000 tab pack varies | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 68.400 |
| Modrex 25 Tablets | Tablet 25 mg | 1000 tab pack varies | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 73.950 |
| Monozide 25 tablet | Tablet 25 mg | 1000 tab pack varies | THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN | 75.230 |
| Diostar-Plus | Film-Coated Tablet 12.5 mg, 160 mg | 500 F.C Tab pack varies | Pharma International Company/ Jordan | 99.750 |
| Arbiten Plus 160/12.5 Tablet | Tablet 12.5 mg, 160 mg | 500 tab pack varies | Jordan Sweden Medical & Sterilization Co. | 104.260 |
| Arbiten plus Tablet | Tablet 25 mg, 160 mg | 500 tab pack varies | Jordan Sweden Medical & Sterilization Co. | 104.260 |
| Co-Anginet | Tablet 12.5 mg, 160 mg | 600 tab pack varies | UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN | 122.230 |
| Procard Plus | Tablet 300 mg, 12.5 mg | 1000 tab pack varies | Al-Taqqadom Pharmaceutical Industries | 159.520 |
| Arbiten Plus 80/12.5 Tablet | Tablet 12.5 mg, 80 mg | 1000 tab pack varies | JORDAN SWEDEN MEDICAL&STERILE.CO(JOSWE)/JORDAN | 176.800 |